<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Symptom Advice .com &#187; beta interferon</title>
	<atom:link href="http://symptomadvice.com/tag/beta-interferon/feed/" rel="self" type="application/rss+xml" />
	<link>http://symptomadvice.com</link>
	<description></description>
	<lastBuildDate>Tue, 29 May 2012 22:17:13 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.0.1</generator>
		<item>
		<title>Novartis gains positive CHMP opinion for Gilenya®, first oral multiple sclerosis treatment recommended for approval in the European Union</title>
		<link>http://symptomadvice.com/novartis-gains-positive-chmp-opinion-for-gilenya%c2%ae-first-oral-multiple-sclerosis-treatment-recommended-for-approval-in-the-european-union/</link>
		<comments>http://symptomadvice.com/novartis-gains-positive-chmp-opinion-for-gilenya%c2%ae-first-oral-multiple-sclerosis-treatment-recommended-for-approval-in-the-european-union/#comments</comments>
		<pubDate>Thu, 03 Feb 2011 04:51:09 +0000</pubDate>
		<dc:creator>Symptom Advice</dc:creator>
				<category><![CDATA[sclerosis symptoms]]></category>
		<category><![CDATA[beta interferon]]></category>
		<category><![CDATA[interferon beta 1a]]></category>
		<category><![CDATA[international ag]]></category>
		<category><![CDATA[relapsing remitting ms]]></category>
		<category><![CDATA[reuters]]></category>
		<category><![CDATA[thomson]]></category>

		<guid isPermaLink="false">http://symptomadvice.com/novartis-gains-positive-chmp-opinion-for-gilenya%c2%ae-first-oral-multiple-sclerosis-treatment-recommended-for-approval-in-the-european-union/</guid>
		<description><![CDATA[Novartis International AG /Novartis gains positive CHMP opinion for Gilenya®, &#102;&#105;&#114;&#115;&#116; oral multiple sclerosis treatment recommended for approval &#105;&#110; &#116;&#104;&#101; European Union Processed &#097;&#110;&#100; transmitted &#098;&#121; Thomson Reuters.&#116;&#104;&#101; issuer is solely responsible for &#116;&#104;&#101; content &#111;&#102; &#116;&#104;&#105;&#115; announcement. * Gilenya recommended &#105;&#110; &#116;&#104;&#101; EU for people with highly active relapsing- remitting MS &#100;&#101;&#115;&#112;&#105;&#116;&#101; treatment with [...]]]></description>
			<content:encoded><![CDATA[<p></p><p><img src="http://symptomadvice.com/wp-content/uploads/2011/02/1296708669-92.jpg" style="clear:both;clear:both;margin:0 15px 15px 0;width:500px" />
<p>Novartis International AG /Novartis gains positive CHMP opinion for Gilenya®, &#102;&#105;&#114;&#115;&#116; oral multiple sclerosis treatment recommended for approval &#105;&#110; &#116;&#104;&#101; European Union Processed &#097;&#110;&#100; transmitted &#098;&#121; Thomson Reuters.&#116;&#104;&#101; issuer is solely responsible for &#116;&#104;&#101; content &#111;&#102; &#116;&#104;&#105;&#115; announcement. </p>
<p> * Gilenya recommended &#105;&#110; &#116;&#104;&#101; EU for people with highly active relapsing- remitting MS &#100;&#101;&#115;&#112;&#105;&#116;&#101; treatment with beta interferon, &#111;&#114; &#105;&#110; patients with rapidly evolving severe relapsing-remitting MS</p>
<p> * Gilenya &#115;&#104;&#111;&#119;&#101;&#100; superior efficacy &#116;&#111; interferon beta-1a IM, a commonly prescribed treatment, reducing relapses &#098;&#121; 52% (p</p>
]]></content:encoded>
			<wfw:commentRss>http://symptomadvice.com/novartis-gains-positive-chmp-opinion-for-gilenya%c2%ae-first-oral-multiple-sclerosis-treatment-recommended-for-approval-in-the-european-union/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
